• BurgoyneDouglas SDSAdjunct Associate Professor, Department of Pharmacotherapy, at the University of Utah College of Pharmacy, Salt Lake City, UT. Email: doug.burgoyne@utah.edu..
• Adjunct Associate Professor, Department of Pharmacotherapy, at the University of Utah College of Pharmacy, Salt Lake City, UT. Email: doug.burgoyne@utah.edu.
• Am J Manag Care. 2022 Sep 1; 28 (9 Suppl): S166S174S166-S174.

AbstractChronic cough (CC), defined as a daily cough lasting longer than 8 weeks in adults, is a common condition in the United States. CC is a diagnosis of exclusion associated with a substantial economic burden related to increased healthcare and medication utilization, decreased work productivity, a greater incidence of cough-related comorbidities, and reduced quality of life. CC treatment guidelines recommend stepwise treatment with specific nonpharmacologic therapies and pharmacologic agents. However, many patients may still have incomplete or no symptom relief, encounter response attenuation over time, or experience intolerable adverse effects. New targeted therapies for refractory CC are currently under development, including the purinergic 2X3 receptor antagonists gefapixant, BLU-5937, and sivopixant (S-600918) and the neurokinin-1 receptor antagonist orvepitant. These targeted agents may have improved efficacy and safety profiles, helping fill unmet treatment needs. If approved, managed care organizations must develop formulary placement and utilization management criteria based on clinical guideline recommendations, expert opinion, and cost-effectiveness analyses to support the clinically appropriate use of these targeted therapies for best patient outcomes.

10 keywords...

hide…